↓ Skip to main content

Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-C…

Overview of attention for article published in BMC Cancer, April 2019
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
17 Dimensions

Readers on

mendeley
44 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study)
Published in
BMC Cancer, April 2019
DOI 10.1186/s12885-019-5526-3
Pubmed ID
Authors

Taro Iguchi, Satoshi Tamada, Minoru Kato, Sayaka Yasuda, Takeshi Yamasaki, Tatsuya Nakatani

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 44 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 8 18%
Student > Bachelor 7 16%
Lecturer 3 7%
Other 3 7%
Researcher 3 7%
Other 4 9%
Unknown 16 36%
Readers by discipline Count As %
Medicine and Dentistry 11 25%
Sports and Recreations 2 5%
Biochemistry, Genetics and Molecular Biology 2 5%
Nursing and Health Professions 2 5%
Agricultural and Biological Sciences 1 2%
Other 5 11%
Unknown 21 48%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 November 2020.
All research outputs
#18,769,480
of 23,262,131 outputs
Outputs from BMC Cancer
#5,505
of 8,424 outputs
Outputs of similar age
#266,905
of 353,670 outputs
Outputs of similar age from BMC Cancer
#147
of 206 outputs
Altmetric has tracked 23,262,131 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,424 research outputs from this source. They receive a mean Attention Score of 4.4. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 353,670 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 206 others from the same source and published within six weeks on either side of this one. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.